Claudio Jommi

Government, Health and Not for Profit

Professor of Practice

Health Policy

claudio.jommi@unibocconi.it

Download v-card Download pdf

Biografia

Claudio Jommi è Professor of Practice in Health Policy presso SDA Bocconi School of Management - Government, Health and Not for Profit Knowledge Group.

È inoltre Membro del Comitato Esecutivo, Direttore dell'Area Politiche Sanitarie e Coordinatore Scientifico dell'Osservatorio Farmaceutico del Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi. È Direttore del Master in International Health Care Management Economics and Policy (MIHMEP). Claudio è stato visiting professor presso Essec Business School, Cergy (Parigi), Herivan K. Haub School of Business, St Joseph University, Philadelphia ( US), presso l’Andrija School of Public Health, Zagabria e l'Università di Claude Bernard Lyon 1 (European Market Access University Diploma) (Parigi). È stato inoltre Presidente dell'Associazione Italiana di Economia Sanitaria (2014-2017).

La sua attività di ricerca è focalizzata sull'accesso al mercato dei farmaci e altre tecnologie mediche, Economia Farmaceutica, le Politiche e la Gestione, la Valutazione delle tecnologie sanitarie e il processo decisionale in ambito sanitario.

I suoi lavori sono stati pubblicati su riviste internazionali e nazionali, tra cui BMJ Open, Drug Design Development and Therapy, Frontiers in Pharmacology, European Journal of Health Economics, Health Policy, International Journal of Health Planning and Management, Journal of Medical Marketing, Pharmacoeconomics, PLOS and PLOS Neglected Diseases, Public Money and Management, Social Science and Medicine, Value in Health.

Ambito di insegnamento Policy Impact Analysis Comparative Health Care Systems Pharmaceutical and Other Medical Technologies Markets

Pubblicazioni recenti

Ronco V., Dilecce M., Lanati E., Canonico P. L., JOMMI C. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? Journal of Pharmaceutical Policy and Practice, 2021, vol.14, no. 1, pp.30

ROGNONI C., BERTOLANI A., JOMMI C. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects Clinical Drug Investigation, 2021, vol.41, no. 4, pp.303-319

Galeone C., Bruzzi P., JOMMI C. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system BMJ Open, 2021, vol.11, no. 1, pp.e041259

Pruneri G., De Braud F., Sapino A., Aglietta M., Vecchione A., Giusti R., Marchiò C., Scarpino S., Baggi A., Bonetti G., Franzini J. M., Volpe M., JOMMI C. Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? PharmacoEconomics - Open, 4 Marzo, 2021

JOMMI C., ARMENI P., BERTOLANI A., COSTA F., OTTO M. The future of Funds for Innovative Medicines: results from a Delphi Study Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2021, vol.8, pp.22-28

ARMENI P., BORSOI L., FORNARO G., JOMMI C., COLOMBO N., COSTA F. Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 7, pp.1192-1209

Download

Grants & Premi

Gestione dei fondi per farmaci innovativi - MSD Oncology , 2020

Valuation of the EQ-5D-5L in Italy - EuroQol Research Foundation , 2019

Direttore

MIHMEP

Master of International Healthcare Management, Economics and Policy

Lingua INGLESE

Durata totale Un anno

Data inizio 26 set 2021